Sanofi
ENXTPASAN enters the week carrying two bruises at once — a regulatory headline that spooked investors, and a lending market that flashed its most aggressive signal in months. The catalyst landed on May 6. STAT News reported that Sanofi had asked to withdraw a diabetes drug from the FDA's priority review voucher programme after a political appointee interfered with the review process…
Short interest % of float, cost to borrow, utilization, and put/call ratio for SAN are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 6 May 2026
SAN enters the week carrying two bruises at once — a regulatory headline that spooked investors, and a lending market that flashed its most aggressive signal in months. The catalyst landed on May 6. STAT News reported…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SAN — free to start on ORTEX.
Sign up for free →Open SAN on ORTEX